Eli Lilly and Company (LLY): One of the Top Stocks to Buy Right Now According to AI

We just covered the 10 Best Stocks to Buy Right Now According to AI and Eli Lilly and Company (NYSE:LLY) ranks 4th on this list.

Eli Lilly and Company (NYSE:LLY) is a premier global pharmaceutical corporation dedicated to discovering, developing, and manufacturing innovative human medicines across multiple therapeutic areas. The company’s primary growth catalyst is its world-class cardiometabolic health portfolio, led by the highly successful tirzepatide molecule, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Eli Lilly also maintains a prominent market presence in oncology with Jaypirca, immunology with Omvoh and Ebglyss, and neuroscience with Kisunla, an advanced treatment targeting Alzheimer’s disease.

Eli Lilly and Company (NYSE:LLY) relies on heavy reinvestment into clinical research and development, combined with expansion of global manufacturing capacity. The firm recently posted the Q1 2026 financial report that recorded total revenue of $19.8 billion, representing a 56% year-over-year increase, fueled almost entirely by the demand for Mounjaro and Zepbound, which collectively brought in $12.8 billion. Non-GAAP diluted earnings per share skyrocketed by 156% year-over-year to $8.55, vastly exceeding analyst forecasts of $6.97. Eli Lilly maintained a superb gross margin of 82.6%, while its non-GAAP performance margin expanded by 7 percentage points to 50%. Backed by this commercial momentum, management raised its full-year 2026 revenue guidance to $82 billion to $85 billion.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Growth Stock Portfolio: 12 Stock Picks by Carl C. Icahn and Chris Rokos Stock Portfolio: Top 10 Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1